Ribavirin-Astrafarm 200mg 60 capsules Рибавирин

Ribavirin Indications

Treatment of chronic hepatitis C (CHC) in combination with other drugs.

Ribavirin Contradictions

- Hypersensitivity to ribavirin or to any of the excipients.
- Severe heart disease, including unstable and uncontrolled forms, observed within 6 months before treatment.
- Severe debilitating diseases.
- Chronic renal failure or creatinine clearance <50 ml / min and / or conditions requiring hemodialysis.
- Severe hepatic impairment (Child-Pugh classification B or C) or decompensated liver cirrhosis.
- Peginterferon alfa-2b is contraindicated in patients co-infected with hepatitis C / HIV virus, cirrhosis of the liver and impaired liver function> 6 points according to the Child-Pugh classification.
- Presence of anamnestic or clinical evidence of a severe mental disorder, including major depression, suicidal ideation, or suicide attempt in children.
- History of autoimmune hepatitis or other autoimmune diseases (due to combination with peginterferon alfa-2b or interferon alfa-2b).
- Hemoglobinopathies (eg thalassemia, sickle cell anemia).
- Pregnancy. Ribavirin-Astrapharm treatment should only be started after receiving a negative pregnancy test immediately before treatment.
- Breastfeeding period.
- Men whose women are pregnant.

Dosage & Administration

Therapy should be performed by a physician experienced in the treatment of chronic hepatitis C. Ribavirin-Astrapharm should be taken twice daily (morning and evening) with food. Due to the teratogenic potential of ribavirin, the capsules should not be broken.

Ribavirin should be used in combination with peginterferon alfa-2a or interferon alfa-2a. The exact dose and duration of the drug depends on the interferon used.

Additional information on dosage and duration of use can be found in the instructions for medical use of peginterferon alfa-2a or interferon alfa-2a when ribavirin is used in combination with one of these drugs.